In silicoregenerative medicine: how computational tools allow regulatory and financial challenges to be addressed in a volatile market

The cell therapy market is a highly volatile one, due to the use of disruptive technologies, the current economic situation and the small size of the market. In such a market, companies as well as academic research institutes are in need of tools to advance their understanding and, at the same time, reduce their R&D costs, increase product quality and productivity, and reduce the time to market. An additional difficulty is the regulatory path that needs to be followed, which is challenging in the case of cell-based therapeutic products and should rely on the implementation of quality by design (QbD) principles. In silicomodelling is a tool that allows the above-mentioned challenges to be addressed in the field of regenerative medicine. This review discusses such in silicomodels and focuses more specifically on the bioprocess. Three (clusters of) examples related to this subject are discussed. The first example comes from the pharmaceutical engineering field where QbD principles and their implementation through the use of in silicomodels are both a regulatory and economic necessity. The second example is related to the production of red blood cells. The described in silicomodel is mainly used to investigate the manufacturing process of the cell-therapeutic product, and pays special attention to the economic viability of the process. Finally, we describe the set-up of a model capturing essential events in the development of a tissue-engineered combination product in the context of bone tissue engineering. For each of the examples, a short introduction to some economic aspects is given, followed by a description of the in silicotool or tools that have been developed to allow the implementation of QbD principles and optimal design.